Contact Us

The choice depends on the experimental question. DDIAS (DNA damage-induced apoptosis suppressor, also designated NOXIN/C11orf82) has been characterized as an anti-apoptotic factor with emerging roles in cancer biology. The Knockout line is appropriate for asking whether DDIAS is required for predicted activities — DDIAS has been characterized as a DNA damage-induced anti-apoptotic factor that contributes to chemotherapy resistance in some cancer contexts. Overexpression is useful for studying DDIAS gain-of-function effects. For cancer biology research, the EDITGENE DDIAS Knockout in HeLa provides a clean genetic background for characterizing DDIAS-specific functions in apoptosis and chemotherapy response. Rescue with wild-type DDIAS is the standard specificity control. The knockout is valuable for studying DDIAS biology, chemotherapy resistance mechanisms, and emerging DDIAS-related cancer therapeutic strategies.

Yes. DDIAS rescue experiments require attention to less-characterized protein architecture: • Construct design: use a codon-modified DDIAS sequence with a small C-terminal tag (FLAG, HA). DDIAS architecture is partially characterized — preserve protein integrity. • Discovery-oriented rescue: parallel wild-type rescue during phenotypic characterization distinguishes DDIAS-dependent phenotypes. • Functional readout: rescue should restore DDIAS-dependent apoptosis suppression and chemotherapy resistance. HeLa transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying DCAF16 (DDB1- and CUL4-associated factor 16)'s role as a CRL4 substrate receptor or modeling its emerging applications in covalent molecular glue degraders. The Knockout line is the standard tool for asking whether DCAF16 is required for these processes — DCAF16 is one of the ~70 DCAF (DDB1- and CUL4-associated factor) substrate receptors that, together with DDB1 and CUL4A/4B, form CRL4 E3 ubiquitin ligase complexes; DCAF16 contains a key surface cysteine (C58, C107, or other) recently characterized as a target for covalent molecular glue degraders. Overexpression is useful for studying DCAF16 in heterologous expression contexts. For targeted protein degradation research, the EDITGENE DCAF16 Knockout in HeLa is uniquely valuable — DCAF16 has emerged as one of the most promising targets for covalent molecular glue degrader (CovGD) development, with recent studies (Henning et al. 2022; Pluciński et al. 2023) showing that small molecules can covalently engage DCAF16 cysteines to recruit neo-substrates for degradation. Rescue with wild-type or cysteine-mutant (C58A, C107A) DCAF16 enables systematic characterization of covalent molecular glue mechanism. The knockout is a critical specificity tool for emerging DCAF16-recruiting covalent degraders and broader exploration of cysteine-reactive molecular glue platforms — DCAF16 is at the forefront of the covalent TPD field.

Yes, and rescue experiments are uniquely powerful for covalent molecular glue research: • Construct design: use a codon-modified DCAF16 sequence with a small C-terminal tag (FLAG, HA). DCAF16 contains the WD40-like substrate-receptor region with key surface cysteines (C58, C107, others) — preserve all elements. • Cysteine-to-alanine rescue: C58A, C107A, and other cysteine mutations enable systematic characterization of which cysteines are required for covalent molecular glue recruitment — this is the gold-standard approach for understanding covalent ligand-DCAF16 mechanism. • Functional readout: rescue should restore CRL4-DCAF16 complex assembly and substrate ubiquitination; covalent molecular glue degrader activity requires the specific cysteine being engaged. HeLa transduces efficiently with lentivirus and supports systematic cysteine mutation analysis for the rapidly emerging covalent molecular glue degrader field.

The choice depends on whether you are studying GBA1 (β-glucocerebrosidase, GCase)'s role as the lysosomal glucocerebroside hydrolase or modeling Gaucher disease and GBA1-associated Parkinson's disease risk. The Knockout line is the standard tool for asking whether GBA1 is required for these processes — GBA1 is a lysosomal hydrolase that cleaves the β-glycosidic bond of glucosylceramide (glucocerebroside) to generate ceramide and glucose; GBA1 deficiency causes intra-lysosomal accumulation of glucocerebroside (Gaucher disease) and is the strongest genetic risk factor for Parkinson's disease (heterozygous GBA1 mutations confer ~5-fold PD risk). Overexpression is useful for studying GBA1 in heterologous expression contexts. For lysosomal storage disease and Parkinson's research, the EDITGENE GBA1 Knockout in HeLa is highly informative — HeLa's flat morphology makes it ideal for imaging-based lysosomal studies. Rescue with wild-type or patient-derived mutant (N370S, L444P, RecNciI) GBA1 enables disease genotype-function studies of Gaucher disease and GBA1-PD. This product complements the parallel GBA1 Knockout in HEK293 (also available). The knockout is a critical specificity control for imiglucerase/Cerezyme, velaglucerase alfa, taliglucerase alfa (recombinant GCase enzyme replacement therapy), ambroxol (clinically-evaluated GCase pharmacological chaperone for GBA1-PD), and emerging GBA1-targeted PD therapeutics.

Yes. GBA1 rescue experiments are well-established for lysosomal research: • Construct design: use a codon-modified GBA1 sequence with a small C-terminal tag (FLAG, HA). GBA1 has N-terminal signal peptide (cleaved), TIM-barrel catalytic domain — N-terminal tags must not disrupt signal peptide processing and lysosomal trafficking. • Lysosomal localization validation: confirm LAMP1 co-localization before functional assays. • Catalytically-dead rescue: E235A/E340A active site glutamate mutations abolish hydrolase activity. • Patient mutation rescue: N370S (mild Gaucher Type 1), L444P (severe Type 2/3), and RecNciI mutations for disease genotype-function studies. • Functional readout: rescue should restore GCase activity (4-MU-Glc cleavage) and reduce GlcCer accumulation. HeLa transduces efficiently with lentivirus and supports imaging-based rescue analysis.

The choice depends on whether you are studying Fut8 (α-1,6-fucosyltransferase 8)'s role as the principal core fucosyltransferase or modeling the industrial application of afucosylated antibody production. The Knockout line is the standard tool for asking whether Fut8 is required for core fucosylation — Fut8 catalyzes the addition of fucose to the innermost GlcNAc of N-glycan chains via α-1,6 linkage, generating 'core fucosylation' that is present on most mammalian N-glycoproteins including the IgG Fc region. Overexpression is useful for studying Fut8 in heterologous contexts. For biopharmaceutical research, the EDITGENE Fut8 Knockout in CHO-K1 is the industry-standard platform — CHO-K1 is the principal cell line for recombinant antibody production, and Fut8 KO generates afucosylated antibodies with enhanced ADCC activity (the basis of POTELLIGENT and similar industrial platforms). Mogamulizumab (anti-CCR4 for cutaneous T-cell lymphoma) and other approved afucosylated antibodies were produced in Fut8-defective CHO-K1-derived lines. Rescue with wild-type Fut8 restores fucosylation. The knockout is uniquely valuable for studying core fucosylation biology and producing afucosylated therapeutic antibodies with enhanced effector function.

Yes. Fut8 rescue experiments are well-established for glycoengineering research: • Construct design: use a codon-modified Fut8 sequence with a small C-terminal tag (FLAG, HA). Fut8 has N-terminal cytosolic tail, single transmembrane span (Golgi anchor), stem region, and C-terminal catalytic domain — preserve Golgi-anchoring architecture. • Catalytically-dead rescue: GDP-fucose-binding or substrate-binding pocket mutations abolish fucosyltransferase activity. • Rescue validates KO specificity: WT Fut8 rescue restores core fucosylation, providing on-target controls for the afucosylated antibody platform. • Functional readout: rescue should restore N-glycan core fucosylation measured by mass spectrometry and LCA (Lens culinaris agglutinin) lectin binding. CHO-K1-specific considerations: • CHO-K1 is a Chinese hamster ovary cell line — the principal industrial cell line for recombinant therapeutic protein production, including monoclonal antibodies. • Lentiviral transduction is supported with moderate efficiency. • Fut8 KO in CHO-K1 generates an afucosylated production platform — antibodies produced from this line lack core fucose, conferring enhanced ADCC activity (the basis of POTELLIGENT and similar industrial platforms).

The choice depends on the experimental question. FXYD6 (FXYD domain containing ion transport regulator 6) is a member of the FXYD family of small transmembrane proteins that modulate Na⁺/K⁺-ATPase activity and have emerging associations with schizophrenia susceptibility. The Knockout line is appropriate for asking whether FXYD6 is required for predicted activities — FXYD family proteins (FXYD1/phospholemman, FXYD2/γ-subunit, FXYD4/CHIF, FXYD6) bind Na⁺/K⁺-ATPase α-subunits to modulate enzyme kinetics, Na⁺/K⁺ affinity, and tissue-specific function; FXYD6 is principally expressed in cochlea and brain, and has been associated with schizophrenia by GWAS. Overexpression is useful for studying FXYD6 in heterologous expression contexts. For FXYD family research, the EDITGENE FXYD6 Knockout in HEK293 enables clean genetic background studies — HEK293 supports systematic structure-function studies. Other FXYD family member expression analysis aids interpretation given partial functional overlap. Rescue with wild-type or Na⁺/K⁺-ATPase-binding-deficient FXYD6 enables structure-function studies. This product complements the parallel FXYD6 Knockout in HCT 116 (also available) for cross-background validation. The knockout is valuable for studying FXYD6's role in Na⁺/K⁺-ATPase regulation and emerging schizophrenia susceptibility biology.

Yes. FXYD6 rescue experiments require attention to small transmembrane protein architecture: • Construct design: use a codon-modified FXYD6 sequence with a small intracellular C-terminal tag (FLAG, HA) — FXYD6 is a small (~95 aa) protein with N-terminal signal peptide, FXYD-motif-containing extracellular region, single transmembrane span, and short cytoplasmic tail; preserve membrane topology. • Surface localization validation: confirm plasma membrane localization by cell surface staining before functional assays. • Na⁺/K⁺-ATPase-binding-deficient rescue: FXYD motif mutations (the conserved PFXYD core) disrupt α-subunit binding and serve as the standard specificity control. • Functional readout: rescue should restore FXYD6-dependent Na⁺/K⁺-ATPase kinetic modulation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

Important nomenclature clarification: DTWD1 (DTW domain containing 1) was historically annotated through homology, but biochemical characterization (Takakura et al. Nature Communications 2019) has established that DTWD1 is a tRNA aminocarboxypropyltransferase that catalyzes acp³U (3-(3-amino-3-carboxypropyl)uridine) modification at tRNA position 20 — DTWD1 is NOT a pseudouridine synthase despite some annotation databases suggesting this. The choice between knockout and overexpression depends on whether you are studying acp³U tRNA modification biology in human cells. The Knockout line is the standard tool for asking whether DTWD1 is required for acp³U modification at tRNA position 20 — DTWD1 uses S-adenosylmethionine (SAM) as the aminocarboxypropyl donor; DTWD1 and DTWD2 are the human homologs of E. coli TapT. For tRNA modification research, the EDITGENE DTWD1 Knockout in HEK293 enables study of acp³U modification biology. This product complements the parallel DTWD1 Knockout in AML12 (mouse hepatocyte, also available) and the DTWD1 & DTWD2 Double Knockout in HEK293 (also available) for cross-species and paralog-specific studies. Rescue with wild-type or catalytically-dead DTWD1 enables structure-function studies. The knockout is valuable for studying tRNA modification, translation fidelity, and emerging tRNA modification-related cancer biology — DTWD1 dysregulation has been reported in several malignancies.

Yes. DTWD1 rescue experiments require attention to acp³U transferase architecture: • Construct design: use a codon-modified DTWD1 sequence with a small C-terminal tag (FLAG, HA). DTWD1 has the DTW domain containing the active site — preserve domain integrity. • Catalytically-dead rescue: active site residue mutations abolish aminocarboxypropyltransferase activity and serve as the standard specificity control. • Functional readout: rescue should restore tRNA acp³U levels at position 20 measured by HPLC-MS. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying EGR1's role as an immediate-early gene transcription factor or its functions in lung cancer and cell proliferation. The Knockout line is the standard tool for asking whether EGR1 is required for these processes — EGR1 (early growth response 1, Zif268, Krox-24, NGFI-A) is a zinc finger transcription factor rapidly induced (within minutes) by growth factors, serum, stress, and neuronal activity; EGR1 binds GC-rich GCG(G/T)GGGCG response elements to drive expression of TGF-β, PTEN, p53, and other target genes. Overexpression is useful for studying EGR1 gain-of-function effects. For lung cancer research, the EDITGENE EGR1 Knockout in A-549 is highly relevant — A-549 is an NSCLC cell line, and EGR1 has been characterized with context-dependent roles in lung cancer (both tumor suppressor and oncogenic in different contexts). Rescue with wild-type or DNA-binding-deficient EGR1 enables structure-function studies. The knockout is valuable for studying immediate-early gene biology, EGR1-mediated transcriptional responses, and emerging EGR1-related cancer biology.

Yes. EGR1 rescue experiments require attention to zinc finger architecture: • Construct design: use a codon-modified EGR1 sequence with a small C-terminal tag (FLAG, HA). EGR1 has N-terminal transactivation domain, three C2H2 zinc fingers (DNA binding), and C-terminal repressor-binding (NAB1/2) region — preserve all elements. • DNA-binding-deficient rescue: zinc finger mutations abolish GCG(G/T)GGGCG element binding. • Functional readout: rescue should restore EGR1-induced target gene expression (TGF-β1, PTEN). A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying FXYD6 in a complementary epithelial cancer background for cross-validation of FXYD6-dependent phenotypes. The Knockout line in HCT 116 is appropriate for asking whether FXYD6 is required for Na⁺/K⁺-ATPase modulation in colorectal cancer context. Overexpression is useful for studying FXYD6 in heterologous expression contexts. For FXYD6 research, the EDITGENE FXYD6 Knockout in HCT 116 provides a cancer epithelial cell background for cross-validation. This product complements the parallel FXYD6 Knockout in HEK293 (also available); cross-background validation strengthens characterization of FXYD6-dependent phenotypes. Rescue with wild-type FXYD6 is the standard specificity control. The knockout is valuable for studying FXYD6 in epithelial Na⁺/K⁺-ATPase regulation.